04 Nov 2025
Providers practicing whole person care increasingly seek tools that assess systemic dysfunction beyond traditional biomarkers. Labcorp’s Metabolic Vulnerability Index (MVX) and MVX Plus assays offer a novel, nuclear magnetic resonance (NMR) spectroscopy-based approach to evaluating mortality risk through the lens of metabolic dysfunction, malnutrition, and inflammation. Originally validated in adults at elevated cardiovascular risk, MVX is now gaining traction for its ability to quantify physiological resilience and near-term mortality risk in patients with liver disease as well as in the general population.
Author
Margery A. Connelly, PhD, MBA
Strategic Director
Diagnostics Research & Development
Cardiometabolic Disease Discipline Director